Anti CP IgG

Key Features and Values
  • Same sample type can be used across all assays to simplify inclusion into routine serology work-up
  • Ready to use reagents reduces hands-on time for assay preparation
  • Long shelf life cost-effective solution by reducing wastage due to expired kits
  • Suitable for inclusion on automated plate systems simplifies scale-up of test volume
  • Supported by a complete panel of assays for diagnosis of SLE and APS
Product Description

Anti CP IgG is an indirect solid phase enzyme immunometric assay (ELISA) kit designed for the quantitative measurement of IgG class antibodies directed against Citrullinated Peptides (CP) in human serum or plasma. Anti CP IgG kit is intended for laboratory use only.

Scientific Description
Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases and the most common autoimmune joint disease. The most common clinical symptom of RA is abnormal inflammation in the synovium causing pain, swelling and stiffness of the affected joint(s).
RA can prove difficult to diagnose in the early phases as the signs and symptoms mimic several other diseases.
Initial serological assessments involved measurement of Rheumatoid Factor (RF) antibodies which are present in up to 80% of RA patients. However, RF is not a very specific marker as these are present in other inflammatory diseases. A more specific biomarker is anti-citrullinated peptide (CP) autoantibodies the presence of which are considered a hallmark of RA and are believed to play a role in disease pathogenesis1,2. Anti- CP antibodies recognise different citrullinated substrates, such as filaggrin, fibrinogen, vimentin, collagen II, enolase3 and histones4,5.
Anti- CP autoantibodies may be present in patients with RA for many years before the onset of the clinical disease4,6. Due to their importance as a tool for diagnosis of RA, measurement of these are included in the serological work up for disease classification7-9.

1. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, et al.  Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens.  Annals of the Rheumatic Diseases 2010;69:A8
2. Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maśliński W.  The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis.  Cent Eur J Immunol. 2017; 42(4): 390–398
3. Uysal H, Nandakumar KS, Kessel C, et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010;233:9-33
4. Manca ML, Alunno A, D’Amato C, et al.  Anti -citrullinated peptide antibodies profiling in established rheumatoid arthritis. Joint Bone Spine. 2018 Jul;85(4):441-445
5. Pratesi F, Panza F, Paolini I, Petrelli F, Puxeddu I, Casigliani-Rabl S, Ancillotti D, Alcaro C, Rovero P, Migliorini P. Fingerprinting of anti-citrullinated protein antibodies (ACPA): specificity, isotypes and subclasses. Lupus. 2015 Apr;24(4-5):433-41. doi: 10.1177/0961203314560005. Review.
6. Kay J, Upchurch KS.  ACR/EULAR 2010 rheumatoid arthritis classification criteria.  Rheumatology, Volume 51, Issue suppl_6, December 2012, Pages vi5–vi9
7. Aletaha D, Neogi T, Silman AJ, et al.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.  Annals of the Rheumatic Diseases 2010;69:1580-1588
8. NICE guidelines: Rheumatoid arthritis in adults: management
9. Aletaha D, Neogi T, Silman AJ, et al.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.  Arthritis Rheum. 2010 Sep;62(9):2569-81


Please enter your email address to download
Code: DKO149
Clinical Area: ,
Incubation: 30+30+15 min
Sensitivity: 76%
Specificity: 94%
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum, heparin plasma, EDTA plasma
Sample Volume: 10 μL (1:100 predilution)
Assay Range: N/A